OTC Watch

All stocks / BDPT

BIOADAPTIVES, INC. BDPT

Bioadaptives (BDPT): shares outstanding up 1763% in a year, convertible notes mentioned in an 8-K in November 2026, a late 10-Q notice in August 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

DilutionEstimated floatCostly financingLate filing OTCIDNevada, USA
Live quote on OTC Markets

Market listing

Full name
BIOADAPTIVES INC
Market tier
OTC Pink Current
Trading status
Active
Last trade
Nov 16
Source: Stockwatch, 2026-11-17

News headlines

UFC Hall of Famer Michael Bisping Backs Xycota Biosciences' Low-Dose Psilocybin Research on PTSD and Concussion
2026-11-12 08:00 · News Release
BioAdaptives Acquisition Target Xycota Biosciences Launches Free PTSD Tactical & Support Hub for Veterans and First Responders Alongside At-Home Psilocybin Research
2026-11-11 14:05 · News Release
BioAdaptives to Acquire Xycota Biosciences to Pursue the Potential of At Home Psilocybin Treatment
2026-11-05 08:00 · News Release
BioAdaptives Highlights Michael Bisping's MyndMed(TM) Routine in UFC 331 Pre-Show Instagram Video
2026-09-23 10:15 · News Release
BioAdaptives Confirms First Commercial Orders of XcellaraHeart(TM) and Outlines Capital Restructuring Progress
2026-09-03 11:15 · News Release
UFC Hall of Famer Michael Bisping Joins BioAdaptives to Champion MyndSystem(TM)
2026-08-31 05:30 · News Release
BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update
2026-08-13 08:35 · News Release
BioAdaptives Inc. Introduces XcellaraHeart(TM): the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal
2026-08-12 07:30 · News Release
BioAdaptives Explains the Scientific Basis of the Dual-Action Xcellara(TM) "Supply and Direction" Platform
2026-08-04 08:00 · News Release
BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart(TM) Cellular Wellness Formula
2026-08-03 08:00 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Revenue
$18,278
Net loss
($1,557,898)
What it means

It spends more than it earns

Under strain

Customers paid it $18,278 in the year. It lost $1.6 million. For every $1 that came in, about $86.23 went out.

The report says
Cash and cash equivalents
$215,205
Net cash used in operating activities
($516,025)
What it means

The cash could run out soon

Under strain

It had $215,205 in the bank and used about $43,002 a month. At that pace the money lasts about 5 months unless it borrows or sells more shares.

The report says
Total assets
$225,901
Total liabilities
$2,355,957
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $225,901. Its debts and unpaid bills add up to $2.4 million. That is about $10.43 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Dilution2026-11-06

Shares outstanding rose from 12,008,659 (2025-10-17) to 223,677,511 (2026-11-06), up 1763%.

Rule: Shares outstanding up 20% or more in 12 months. Source record

Estimated float2026-11-06

Estimated float about 223,677,511 shares as of 2026-11-06: 223,677,511 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Costly financing2026-11-04

8-K filed 2026-11-04 mentions: convertible note, equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Late filing2026-08-14

Filed NT 10-Q on 2026-08-14: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Late filing2026-03-31

Filed NT 10-K on 2026-03-31: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Shares outstanding

Source: SEC filings
2025-12-31
12.0M
2026-03-24
12.0M
2026-03-31
12.0M
2026-05-01
12.0M
2026-06-30
36.6M
2026-08-13
196.9M
2026-09-30
223.7M
2026-11-06
223.7M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-16 10-QFORM 10-Q
2026-11-04 8-KFORM 8-K
2026-11-04 4FORM 4
2026-10-06 4FORM 4
2026-09-03 4FORM 4
2026-08-19 10-QFORM 10-Q
2026-08-14 NT 10-QFORM NT 10-Q
2026-08-04 4FORM 4
2026-07-06 4FORM 4
2026-06-03 4
2026-05-15 10-QFORM 10-Q
2026-05-05 4FORM 4

Common questions about BDPT

Does BDPT file reports with the SEC?

Yes. Bioadaptives files with the SEC under company number 0001575142. The most recent filing we hold is a 10-Q dated 2026-11-16.

Source record

How many BDPT shares are outstanding?

223,677,511 shares as of 2026-11-06, as reported to the SEC. That is up 1763% from 12,008,659 on 2025-10-17.

Source record

Has BDPT filed reports late?

Yes. In the last 12 months it filed 2 late-filing notices, most recently a NT 10-Q on 2026-08-14. A notice means a report was not ready on time; check whether the report followed.

Source record

Is Bioadaptives making money?

Customers paid it $18,278 in the year. It lost $1.6 million. For every $1 that came in, about $86.23 went out. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record